Pfizer always regards "creating a healthy China" as its mission in China, and promises to actively participate in promoting the development of medical and health undertakings in China and improving people's health. We aim to meet the diversified medical service needs of 654.38+300 million people in China through innovative, socially responsible and commercially feasible ways. In addition to providing a wide range of innovative medical and health products, Pfizer also actively cooperates with relevant government departments, scientific research/medical institutions, academic organizations and social organizations, and actively promotes the development of medical and health undertakings in China by carrying out projects such as patient education, disease promotion, health management, community medical care and personnel training. More than 50 innovative drugs of Pfizer biopharmaceuticals have been listed in China, covering cardiovascular and cerebrovascular diseases and metabolism, anti-infection, central nervous system, anti-inflammatory and analgesic, anti-tumor, urinary and blood health (including hemophilia) and other fields. Among them, Lipitor? , Luo Huoxi? , Viagra? Shu Pushen? , Dafukang? Xi Shu Mei? ，Sotan？ Caputo? , Arnold New? Ren Jie? , Beifu? Many products are in the leading position in the market. In order to enable patients in China to receive advanced drug treatment in time, Pfizer will further increase and speed up the introduction and listing of new drugs in China.
Good storage under Pfizer health drugs? , calcium? , Hui Ningfei? And other consumer health products enjoy a high reputation in the China market, and are favored by consumers for their excellent quality. Pfizer invested more than US$ 654.38 billion in China, and set up four advanced production facilities in Dalian, Suzhou and Wuxi to produce drugs and health care drugs respectively. The products produced not only satisfy the China market, but also are exported to overseas markets. Among them, Pfizer Dalian Pharmaceutical Factory is the first pharmaceutical factory in China to obtain GMP certification in the pharmaceutical industry. In addition, Pfizer also has a management center in Beijing; Established Pfizer Investment Co., Ltd. in Shanghai; We also have R&D centers in Shanghai and Wuhan.
20 12 Pfizer and Zhejiang Haizheng Pharmaceutical Co., Ltd. established Haizheng Pfizer Pharmaceutical Co., Ltd. The joint venture will develop, produce and promote patented expired drugs, including branded generic drugs, for China and the global market. The establishment of the joint venture company marks an important step in the efforts of the two companies to provide high-quality and cheap brand generic drugs for more patients. The Pfizer China R&D Center (CRDC) located in Zhangjiang Hi-Tech Park is an important R&D center of Pfizer in the Asia-Pacific region, providing support services for Pfizer's global R&D projects in the fields of biology, chemistry and pharmacy. In addition to activities related to drug development, the center also has an Asian research team to implement and coordinate Pfizer's Asian research strategy, and cooperate with academic research institutions, clinical experimental institutions (CRO) and government research institutions all over Asia to enhance research capabilities in Asia. Up to now, Pfizer China R&D Center has invested more than US$ 65.438+0.5 billion, has more than 900 R&D personnel, and set up a sub-center in Wuhan Optics Valley Bio-industry Center, greatly expanding its R&D scale and cooperation field in China.
At the same time, Pfizer China R&D Center also cooperates with domestic first-class academic institutions including Peking University, Tsinghua University, Fudan University, Institute of Biophysics of Chinese Academy of Sciences, Shanghai Institute of Biochemistry and Cell Biology of Chinese Academy of Sciences, and carries out cooperative projects in clinical research, pharmacoeconomics and personnel training, so as to continuously promote the development and progress of innovative drugs research and international personnel training in China.